- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2024–2028 · research · R01
Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney Cancer
Eliezer M Van Allen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2027 · grant · PCRP
Genetic Testing, Counseling, and Management of Cancer in Africa
Timothy Rebbeck · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2024 · grant · LCRF Research Grant on Understanding Resistance in Lung Cancer
2024 – LCRF Research Grant on Understanding Resistance in Lung Cancer – Dana-Farber Cancer Institute – William Feng, PhD
William Feng · Dana-Farber Cancer Institute · funded by Lung Cancer Research Foundation
2024–2029 · research · R25
The Young Empowered Scientists for ContinUed Research Engagement (YES for CURE) Program at the Dana-Farber/Harvard Cancer Center (DF/HCC)
James A. Decaprio · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2026 · grant · PRCRP
Longitudinal Study of Circulating Tumor DNA to Identify Mechanisms of Treatment Resistance in Rhabdomyosarcoma
Brian Crompton · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2024–2027 · fellowship · F32
Investigating IGF2BP1 as a novel Therapeutic Target for Ewing Sarcoma
Michael Joseph Bond · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2026 · grant · PRP
Mechanisms of Irisin-Induced Cognitive Benefit in PD
Bruce Spiegelman · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2024–2029 · cooperative agreement · U24
Enhancement and further development of informatics methods for long-read cancer sequencing
Catarina D. Campbell · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · career development · K08
Validation and implementation of ctDNA as a clinically informative biomarkerin AYAs with sarcomas.
David Shulman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2026 · grant · D43
Administrative supplement to expand cancer clinical trial capacity in sub-Saharan Africa
Timothy R Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024 · research
Improving treatments for people with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer
Sara Tolaney · Dana-Farber Cancer Institute · funded by Breast Cancer Research Foundation
2024 · fellowship · AACR-CCF of ASCO Young Investigator Award for Translational Cancer Research
Fusion RNAs as individualized therapeutic targets in advanced breast cancer
Nolan Priedigkeit · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
2024 · career development · Career Development Award
LuCarbo - a phase 1a/1b clinical trial of 177LuPSMA-617 in combination with carboplatin in advanced prostate cancer
Praful Ravi · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2024 · research · AACR-MPM Oncology Charitable Foundation Transformative Research Grant
Identification of lipid-targeted molecular regulators of H3K27M glioma growth
Nika N. Danial · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
2024 · research · Advanced Clinical Research Award
A Phase 1b study of BCL-XL degrader DT2216 in combination with weekly paclitaxel in recurrent platinum-resistant ovarian cancer
Elizabeth Stover · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2024 · fellowship · AACR-Exelixis Renal Cell Carcinoma Research Fellowship
Novel target discovery in translocation renal cell carcinoma
Cary N. Weiss · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
2024 · career development · Young Investigator Award
Fusion RNAs as individualized therapeutic targets in advanced breast cancer
Nolan Priedigkeit · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2024 · career development · Young Investigator Award
IGF1 loss as a molecular driver of liposarcoma de-differentiation
Erica Pimenta · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2024 · career development · Young Investigator Award
The STAR-ACCORD Study: Strength of Therapeutic Alliance Research in AYAs, their Caregivers, and their Oncologists on Relationship Development
Rosemarie Mastropolo · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2024 · fellowship · ASH Research Training Award for Fellows (RTAF): First Year Awardees
ASH Research Training Award for Fellows (RTAF) 2024: Frederick Tsai
Frederick Tsai · Dana-Farber Cancer Institute · funded by American Society of Hematology
2024 · career development · Young Investigator Award
Nutrition assessment to refine a "food is medicine" intervention for childhood cancer survivors
Rahela Aziz-Bose · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2024 · fellowship · QuadW Foundation-AACR Fellowship for Clinical/Translational Sarcoma Research
IGF1 loss as a molecular driver of liposarcoma de-di erentiation
Erica M. Pimenta · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
2024 · career development · Career Development Award
Dissecting mechanisms and novel strategies for overcoming treatment resistance in gastrointestinal stromal tumors (GIST)
Candace Haddox · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2024–2028 · research · R01
Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney Cancer
Eliezer M Van Allen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R01
Assessment of germline variants associated with immune-related adverse events following immune checkpoint inhibitors
Toni Choueiri · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2025 · research · R61
New Chemical Tools for Covalent Drug Discovery
Justin Kim · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2028 · research · R01
Contribution of a novel OPN-producing CD11c+ microglial subset to AD
Harvey Cantor · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2028 · research · R01
Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy
Derin B Keskin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R01
Molecular mechanisms of developmental reprogramming in colorectal cancer
Nilay Sethi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2026 · grant · OT2
PROTECT (Harnessing PROTEin degradation for Advanced Childhood Tumors)
Kimberly Stegmaier · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R01
Variability in Opioid Prescribing Across the Cancer Care Continuum: A Multi-Level Analysis
Andrea C Enzinger · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2025 · career development · K08
Molecular Dynamics of Glioma Formation and DNA Damage Response by Mutant IDH1
Diana Shi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R01
Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder Cancer
Kent W Mouw · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R37
HEME-Hospice: An Intervention to improve Hospice Use for Patients with Hematologic Malignancies
Jennifer W Mack · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · career development · K24
Collaborative Care to Improve Resilience and Quality of Life among Youth with Non-malignant Blood Disorders
Abby R Rosenberg · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · cooperative agreement · U24
Enhancement and further development of informatics methods for long-read cancer sequencing
Catarina D. Campbell · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2028 · research · R00
Dissecting the Role of Germline Genetics in RAS-Driven Cancers
Ryan Lewis Collins · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · career development · K08
BCOR/PRC1.1 Inactivation In Splicing Factor Mutant MDS Progression
Rahul Vedula · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R25
The Young Empowered Scientists for ContinUed Research Engagement (YES for CURE) Program at the Dana-Farber/Harvard Cancer Center (DF/HCC)
James A. Decaprio · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2026 · research · R21
Investigating Interactions Between Radiation and Antibody-Drug Conjugates in Bladder Cancer
Kent W Mouw · Dana-Farber Cancer Institute · funded by National Institutes of Health
